Lupin Offloads US Women's Health Business to Evofem for Up to $84 Million

Indian pharmaceutical giant Lupin has announced the sale of its US-based women's health specialty business to Evofem Biosciences for a potential deal worth up to $84 million. The divestment marks a strategic move by Lupin to concentrate on its core therapeutic areas.

The acquired business is primarily focused on commercializing Solosec, an FDA-approved single-dose treatment for bacterial vaginosis and trichomoniasis. The deal includes potential milestone payments based on future performance.

Lupin's decision aligns with its broader strategy of building a strong specialty business in therapeutic areas like respiratory and neurological diseases. By offloading the women's health unit, Lupin aims to streamline its operations and focus on its core competencies.

The transaction is expected to close in the second half of 2023, subject to customary closing conditions.